{
  "trial_id": "NCT01928589",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "H&E staining) invasive adenocarcinoma of the breast.",
      "label": "met"
    },
    {
      "criterion": "Primary tumor \u2264 4cm and 0-3 positive axillary lymph nodes (T1-2, N0-1, M0).",
      "label": "met"
    },
    {
      "criterion": "Margin negative surgery.",
      "label": "met"
    },
    {
      "criterion": "Patient must have a Medical Oncology consult with the recommendation of chemotherapy.",
      "label": "met"
    },
    {
      "criterion": "ECOG performance status \u2264 1.",
      "label": "met"
    },
    {
      "criterion": "Women of child-bearing potential must have a negative (urine or blood) pregnancy test within 6 weeks prior to start of protocol therapy.",
      "label": "met"
    },
    {
      "criterion": "Ability to understand and the willingness to sign a written informed consent document.",
      "label": "met"
    },
    {
      "criterion": "Partial breast irradiation must be scheduled to begin less than 71 days from the last breast surgical procedure.",
      "label": "met"
    },
    {
      "criterion": "Women of child-bearing potential must also use effective non-hormonal contraception while undergoing radiation treatment and chemotherapy.",
      "label": "met"
    },
    {
      "criterion": "Recommended regimens are as follows: Cyclophosphamide and Doxorubicin (AC); Taxotere, Doxorubicin and Cyclophosphamide (TAC); Taxotere and Cyclophosphamide (TC); or Taxotere, Carboplatin with Trastuzamab (TCH) prior to registration; or Paclitaxel and Trastuzumab.",
      "label": "met"
    },
    {
      "criterion": "The use of additional chemotherapy, hormonal therapy or Trastuzumab after the initial regimen is at the discretion of the Medical Oncologist.",
      "label": "unknown"
    },
    {
      "criterion": "Other primary regimens are possible but the PI must be notified prior to enrollment.",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "hormonal therapy for the current cancer.",
      "label": "not_met"
    },
    {
      "criterion": "Patients with squamous or sarcomas of the breast.",
      "label": "not_met"
    },
    {
      "criterion": "Patient is pregnant.",
      "label": "not_met"
    },
    {
      "criterion": "Patient has a serious medical or physciatric illness which prevents informed consent or adherence with treatment.",
      "label": "unknown"
    }
  ],
  "notes": "42 year-old postmenopausal woman with 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant, HER2-positive and ER/PR negative.",
  "_meta": {
    "topic_id": "25",
    "trial_id": "NCT01928589",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}